Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02775955 · ClinicalTrials.gov registry record · Phase 1

PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

A Phase 1 study of Healthy, sponsored by Pharmaceutical Project Solutions.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT02775955: Completed Phase 1 study of Healthy, sponsored by Pharmaceutical Project Solutions.

NCT02775955 is a Phase 1 study of Healthy that has completed, run by Pharmaceutical Project Solutions. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02775955, a Phase 1 study of Healthy, has completed, sponsored by Pharmaceutical Project Solutions.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the potential effect of renal impairment on the systemic pharmacokinetics of acute Intranasal RX0041-002. The secondary objective is to evaluate the safety and tolerability of acute Intranasal RX0041-002 in subjects with normal renal function and severe renal impairment.

Conditions Studied

Interventions

  • DRUG RX0041

Study Locations (1)

New Jersey

  • Comprehensive Clinical Researc - Berlin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-02
Est. Completion 2016-10
Phase Phase 1

Sponsor

Pharmaceutical Project Solutions

3 total trials

What the Registry Record Tells You About NCT02775955

The ClinicalTrials.gov registry entry for NCT02775955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Pharmaceutical Project Solutions, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which RX0041 is the first listed.

NCT02775955 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02775955 about?

NCT02775955 is a clinical study titled "PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function". The primary objective of this study is to evaluate the potential effect of renal impairment on the systemic pharmacokinetics of acute Intranasal RX0041-002. The secondary objective is to evaluate the safety and tolerability of acute Intranasal RX0041-002 in subjects with normal renal function and se...

What is the current status of trial NCT02775955?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-02. Estimated completion is 2016-10.

What conditions does trial NCT02775955 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02775955?

The interventions under investigation include: RX0041 (DRUG).

Who is sponsoring clinical trial NCT02775955?

This trial is sponsored by Pharmaceutical Project Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02775955 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.